Business

Announcement on Voluntary Disclosure of Obtaining Clinical Trial Approval Notification for Iprinosine Hydrochloride for Injection (BEBT-908) Combined with CHOP in the Treatment of Newly Diagnosed Peripheral T-Cell Lymphoma

Announcement on Voluntary Disclosure of Obtaining Clinical Trial Approval Notification for Iprinosine Hydrochloride for Injection (BEBT-908) Combined with CHOP in the Treatment of Newly Diagnosed Peripheral T-Cell Lymphoma

articleBebetter Med, Inc. Class AMarch 13, 20265/news/announcement-on-voluntary-disclosure-of-obtaining-clinical-trial-approval-notification-for-iprinosine-hydrochloride-for-injection-bebt-908-combined-with-chop-in-the-treatment-of-newly-diagnosed-peripheral-t-cell-lymphoma
Announcement on Voluntary Disclosure of Obtaining Clinical Trial Approval Notification for Iprinosine Hydrochloride for Injection (BEBT-908) Combined with CHOP in the Treatment of Newly Diagnosed Peripheral T-Cell Lymphoma

About this update from Bebetter Med, Inc. Class A

Announcement on Voluntary Disclosure of Obtaining Clinical Trial Approval Notification for Iprinosine Hydrochloride for Injection (BEBT-908) Combined with CHOP in the Treatment of Newly Diagnosed Peripheral T-Cell Lymphoma The abstract is for reference only. Please refer to the full text of the announcement on the very day. Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Bebetter Med, Inc. Class A